Cancer Genetics Inc  

(Public, NASDAQ:CGIX)   Watch this stock  
Find more results for FRANKLYN G. PRENDERGAST
2.04
0.00 (0.00%)
Jul 22 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range 2.03 - 2.06
52 week 1.82 - 11.45
Open 2.03
Vol / Avg. 9,965.00/78,546.00
Mkt cap 32.88M
P/E     -
Div/yield     -
EPS -1.91
Shares 13.65M
Beta 1.11
Inst. own 27%
Aug 9, 2016
Q2 2016 Cancer Genetics Inc Earnings Release (Estimated) - 4:00PM EDT - Add to calendar
May 10, 2016
Q1 2016 Cancer Genetics Inc Earnings Call - Webcast
May 10, 2016
Q1 2016 Cancer Genetics Inc Earnings Release
More events from DailyFinance »    

Key stats and ratios

Q1 (Mar '16) 2015
Net profit margin -86.59% -111.88%
Operating margin -85.42% -118.50%
EBITD margin - -109.28%
Return on average assets -45.39% -42.05%
Return on average equity -68.74% -59.74%
Employees 223 -
CDP Score - -

Address

201 State Rt 17 Fl 2
RUTHERFORD, NJ 07070-2597
United States - Map
+1-201-5289200 (Phone)
+1-201-5289201 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

Cancer Genetics, Inc. is engaged in the field of personalized medicine, enabling precision medicine in the field of oncology through its diagnostic products and services, and molecular markers. The Company develops, commercializes and provides molecular- and biomarker-based tests and services that enable physicians to personalize the clinical management of each individual patient by providing genomic information to diagnose, monitor and inform cancer treatment, and enable biopharmaceutical companies engaged in oncology trials to select candidate populations and manage adverse drug reactions by providing information regarding genomic factors influencing subject responses to therapeutics. It has a range of disease-focused oncology testing portfolio. Its molecular- and biomarker-based diagnostic services are provided for three sectors: cancer centers and hospitals, biotechnology and biopharmaceutical companies, and the research community.

Officers and directors

John G. Pappajohn Chairman of the Board
Age: 87
Bio & Compensation  - Reuters
Panna L. Sharma President, Chief Executive Officer, Director
Age: 44
Bio & Compensation  - Reuters
Edward J. Sitar CPA Chief Financial Officer, Treasurer, Secretary
Age: 47
Bio & Compensation  - Reuters
Rita Shaknovich Medical Director, Vice President - Hematopathology Services
Bio & Compensation  - Reuters
Jane Houldsworth Ph.D. Vice President - Research & Development
Age: 56
Bio & Compensation  - Reuters
Raju S. K. Chaganti Ph.D. Director
Age: 82
Bio & Compensation  - Reuters
Edmund M. Cannon Independent Director
Age: 70
Bio & Compensation  - Reuters
Geoffrey Eric Harris Independent Director
Age: 53
Bio & Compensation  - Reuters
Howard McLeod Independent Director
Age: 49
Bio & Compensation  - Reuters
Franklyn G. Prendergast M.D., Ph.D. Independent Director
Age: 71
Bio & Compensation  - Reuters